DNA Damage and Radiotherapy
A special issue of Biomedicines (ISSN 2227-9059). This special issue belongs to the section "Molecular Genetics and Genetic Diseases".
Deadline for manuscript submissions: closed (30 September 2023) | Viewed by 2454
Special Issue Editor
Special Issue Information
Dear Colleagues,
Radiotherapy (RT) is one of the most common and effective treatment strategies for cancer, which is effective for not only localized but also metastasis tumors. The effectiveness of RT is directly linked to the total exposure dose delivered to the tumor. In principle, any tumor can be controlled if the tumoricidal radiation dose can be delivered. However, tumors are surrounded by normal tissues that are susceptible to irradiation, and are thus injured inevitably. Therefore, side effects of variable severity would be caused, including the development of malignancies. Finally, total exposure dose determination requires a compromise between tumor control and normal tissues protection.
During RT, exposure of cells to ionizing radiation (IR) induces DNA double-strand breaks (DSBs), which are a major cause for lethal damage to the DNA of cancer cells, as well as being responsible for the induction of side effects. The risks posed by DSBs to the genome of higher eukaryotes are mitigated by a network of signaling pathways collectively termed the DNA damage response (DDR). DDR detects DSBs and coordinates a wide spectrum of cellular responses, including checkpoint activation and DSB repair. DDR signaling factors targeting to develop strategies for the better targeting of tumors, while the protection of normal tissues has become a subject of intensive research, such as the utilization and characterization of new radiation modality, the development and investigation of novel inhibitors of individual DSB repair pathways, etc. We, therefore, invite authors to submit original and review articles on these topics.
Dr. Fanghua Li
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Biomedicines is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- radiotherapy
- tumor control
- normal tissue protection
- DNA damage response (DDR)
- radiation modality
- novel inhibitors
